Body Vision
Improving early stage lung cancer biopsy yields
Problem
Lung cancer is the second most common and one of the deadliest cancers globally. The 5-year survival rate among lung cancer patients is below 15% globally. Prognosis of the disease increases exponentially at the earlier stages, however, screening programs are highly ineffective due to widely available diagnostic solutions’ inability to precisely diagnose small nodules at the earliest stages. One of the key issues is the lack of precision of intra-operative visualization tools due to CT to body divergence.
Investment Rationale
Bodyvision is the leading AI intra-operative visualization tool in the market, with accuracy only comparable to CBCT intra-operative suites, widely unavailable for pulmonologists & thoracic surgeons. BodyVision founder, Dorian Averbuch, was a key stakeholder in the development of the Superdimension electronic navigation system, the legacy intra-operative visualization solution.
Dorian’s imaging & visualization expertise, combined with the early traction & results of the company were key in building our conviction to support his vision. He is not only one of the most knowledgeable stakeholders in the medical intra-operative imaging industry but has a deep understanding of the patient customer journey that is allowing BodyVision to thrive in the complex Medtech market.
